Published on 01/12/2025

Spiking Study Design: Model Viruses, Levels, and Matrices

In the realm of biologics and Advanced Therapy Medicinal Products (ATMPs), ensuring viral safety is paramount. This article serves as a comprehensive guide focused on the design and implementation of spiking studies, particularly relevant for viral clearance validation. It elaborates on model viruses, operational levels, and matrix considerations. This tutorial aims to ensure compliance with regulatory expectations from entities such as the US FDA, EMA, MHRA, and ICH guidelines, particularly ICH Q5A(R2).

Understanding Viral Clearance Validation

Viral clearance validation is a crucial process that minimizes the risk of viral contamination in biologics and ATMPs. This validation strategy involves a series of studies designed to assess the removal or inactivation of viruses from a product or therapeutic agent. Validation is particularly essential in the context of closed systems and single-use systems, where the risk of contamination might vary.

According to FDA guidelines, a thorough understanding of the viral introduction routes is fundamental in designing spiking studies. Viruses used in these studies, referred to as model viruses, are typically non-pathogenic and represent a spectrum of potential viral contaminants. Examples include:

• Hemorrhagic Fever Viruses, such as Ebola viruses
• Enveloped viruses like the Vesicular Stomatitis Virus (VSV)
• Non-enveloped viruses such as the Polio Virus

The objective of these studies is to establish quantifiable data on virus clearance efficacy at various processing steps. Regulatory authorities emphasize the need to select model viruses that mimic real-world viral threats while considering the specific attributes of the production process.

Step 1: Selecting Model Viruses for Spiking Studies

The selection of appropriate model viruses is vital for the spiking study design. The chosen model viruses should possess characteristics that allow them to effectively simulate the target pathogens relevant to the production process. Factors to consider in the selection include:

• Virus Size and Type: Size affects the filtration efficacy; therefore, include viruses of varying sizes and types (enveloped vs. non-enveloped).
• Stability in Process Conditions: Model viruses should remain stable under the operational parameters of the manufacturing environment.
• Relevance to Product: Choose viruses that pose a realistic risk to the specific product or class of products being investigated.

When performing spiking studies, it’s necessary to document the chain of identity and custody (COI/COC) for each model virus, ensuring traceability throughout the study. This approach mitigates risks and enhances compliance with cGMP regulations.

Step 2: Establishing Spiking Levels

Establishing appropriate spiking levels entails defining the concentration of the model virus used in the study. This decision should be aligned with the anticipated viral load in the raw materials and the level of sensitivity required to evaluate the clearance steps. Common considerations include:

• Benchmarking Against Known Contaminants: Utilize historical data on viral contaminations in similar processes to set realistic spiking levels.
• Impact of Dilution: Consider the dilution effect of various process steps that may influence viral concentration and ultimately affect validation outcomes involved in viral clearance validation.
• Regulatory Recommendations: Follow guidance from organizations such as the EMA and the WHO regarding suitable levels for spiking studies, typically recommended to be ≥ 10^5 to 10^6 infectious units per mL.

Each spiking study should evaluate a range of levels to ensure robustness in the assessment of viral clearance methods employed in the specific ATMP production process.

Step 3: Designing the Spiking Study Protocol

The study protocol serves as the framework within which the spiking study will be conducted. It should detail all experimental conditions, including the following:

• Preparation of Buffer Solutions: The buffer matrix used in the study should closely resemble the real manufacturing environment to ensure that the results are applicable.
• Model Virus Addition: Precisely document how and when the model virus is introduced into the process.
• Sampling Strategy: Define the frequency and volume of samples taken for viral testing while ensuring consistency across all tests.
• Analytical Methods: Specify the methodologies for quantitative viral determination, such as plaque assays or qPCR, and validate these methods to comply with regulatory standards.

Step 4: Conducting the Spiking Study

Executing the spiking study requires meticulous attention to detail to ensure reproducibility and accuracy throughout the validation. Important aspects during execution include:

• Sanitization of Equipment: Ensure that all equipment and materials used in the study are thoroughly sanitized to prevent cross-contamination.
• Aseptic Controls: Implement robust aseptic controls particularly in accordance with Aseptic Controls Annex 1, which highlights the importance of maintaining aseptic conditions during processing.
• Documentation: Keep comprehensive records of laboratory activities, including any deviations from the protocol and corrective actions taken.

Utilizing closed systems and single-use systems can enhance aseptic processes by reducing the risks associated with traditional multi-use equipment. Proper training and adherence to SOPs (Standard Operating Procedures) are also critical during this stage.

Step 5: Analyzing and Reporting Results

Once the spiking study is complete, it is essential to analyze and interpret the results effectively. This involves:

• Data Processing: Use appropriate statistical methods to assess the clearance efficacy observed at each step of the process. Ensure that results are presented in a clear and understandable format.
• Evaluation of Viral Reduction Effectiveness: Calculate the Log Reduction Value (LRV) achieved through the respective unit operations, and compare it against pre-established thresholds for viral clearance.
• Report Generation: Compile a comprehensive report detailing methodologies, findings, and recommendations. This report should align with the validation lifecycle and maintain adherence to cGMP guidelines.

In your report, ensure that you specify the necessity of modeling and validating the viral clearance for all relevant potency identity Critical Quality Attributes (CQAs), emphasizing the need to establish a clear understanding of viral risks in relation to potency identity.

Step 6: Addressing Regulatory Considerations and Submissions

The final step involves integrating the data derived from spiking studies into regulatory submissions. Whether submitting to the FDA, EMA, or MHRA, it is critical to highlight the proactive measures taken for viral safety. Consider the following:

• Integration with Process Validation: Incorporate viral clearance validation results into broader process validation documents, complying with FDA process validation expectations.
• Review of Regulatory Guidelines: Regularly review and adapt to emerging guidelines and requirements from agencies like PIC/S to maintain compliance and best practices.
• Continuous Improvement: Use the outcomes from spiking studies to improve and refine processes continually, ensuring that validation remains a dynamic and iterative process.

It’s essential to engage in active communication with regulatory agencies to clarify any uncertainties regarding the applicability of results from spiking studies to a given manufacturing context.

Conclusion

Viral clearance studies play a vital role in ensuring the safety and efficacy of biologics and ATMPs. By adhering to a structured approach to designing spiking studies and integrating regulatory guidance into this process, pharmaceutical professionals can ensure compliance and create safer therapeutic products. This tutorial has provided a detailed roadmap for executing spiking studies effectively while aligning with both scientific principles and regulatory expectations.

The integration of the discussed methodologies into routine practice will not only meet the current regulatory expectations but also enhance the quality and safety of biologics produced under the stringent conditions required in pharmaceutical validations.